Preston Klassen's Insider Trades & SAST Disclosures
Preston Klassen's most recent trade in Regulus Therapeutics Inc was a trade of 675,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 30, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Preston Klassen.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc | Preston Klassen | Director, President & Head of R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 675,000 | 675,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Preston Klassen | Director, President & Head of R & D | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 13 Jan 2025 | 31,445 | 36,055 (0%) | 0% | 1.3 | 39,721 | Common Stock |
| Regulus Therapeutics Inc | Preston Klassen | Director, President & Head of R & D | Grant, award, or other acquisition of securities at price $ 1.36 per share. | 09 Jan 2025 | 37,500 | 37,500 (0%) | 0% | 1.4 | 51,000 | Common Stock |
| Regulus Therapeutics Inc | Preston Klassen | Director, President & Head of R & D | Grant, award, or other acquisition of securities at price $ 1.30 per share. | 09 Jan 2025 | 30,000 | 67,500 (0%) | 0% | 1.3 | 39,000 | Common Stock |
| Regulus Therapeutics Inc | Preston Klassen | Director, President & Head of R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 528,000 | 528,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Klassen Preston | Director, President & Head of R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Preston Klassen | Director, President & Head of R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Preston Klassen | President & Head of R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 350,000 | 350,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges